title: [Phase III study of chemotherapy in low-malignancy non-Hodgkin's lymphomas: comparison of vincristine-vindesine combination chemotherapy].
abstract: In a phase-III study in non-Hodgkin's lymphoma of low malignancy we compared a combination therapy with vincristine (COP) with a vindesine combination (CEP). Remission rates, duration of remission and survival was favorable for the CEP combination without reaching the level of significance. The peripheral neurotoxicity of grade 2 and 3 according to WHO criteria was observed more frequently with vincristine. The vincristine-induced neurotoxicity in 6 patients was not impaired when a change was made to vindesine treatment.
authors.affiliation: Onkologisches Zentrum, Klinikum Mannheim.
authors.forename: M E
authors.initials: ME
authors.lastname: Heim
authors.forename: D
authors.initials: D
authors.lastname: Fritze
authors.forename: A D
authors.initials: AD
authors.lastname: Ho
authors.forename: W
authors.initials: W
authors.lastname: Mebes
authors.forename: U
authors.initials: U
authors.lastname: Abel
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage*; D014751:Vindesine / Q000008:administration & dosage*
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D014751:Vindesine; D011241:Prednisone
vernacular_title: Phase-III-Studie zur Chemotherapie niedrig-maligner Non-Hodgkin-Lymphome: Vergleich einer Vincristin- mit einer Vindesin-Kombinations-Chemotherapie.